Advertisement

PharmacoEconomics

, Volume 21, Issue 11, pp 769–790 | Cite as

The Impact of Treatment for Gastro-Oesophageal Reflux Disease on Health-Related Quality of Life

A Literature Review
  • Manishi Prasad
  • Anne M. Rentz
  • Dennis A. Revicki
Review Article

Abstract

Gastro-oesophageal reflux disease (GORD) is common in the general population and is diagnosed based on patient-reported symptoms and clinical tests. Although clinical tests are available, significant percentages of patients report symptoms of heartburn and reflux despite negative endoscopies, and 24-hour pH tests are not often used by primary-care physicians in diagnosis. Consequently, patient-reported symptoms and health-related QOL (HR-QOL) are important in assessing treatment outcome.

HR-QOL is significantly impaired in patients with GORD, and HR-QOL is associated with symptom severity and changes in GORD-related symptoms. The objective of this literature review is to examine the impact of pharmacological treatment on HR-QOL in patients with GORD.

Generic and disease-specific HR-QOL measures have been used in clinical trials to evaluate the impact of GORD on patient functioning and well-being. The Psychological General Well-Being (PGWB) Index and the 36-Item Short-Form Health Survey (SF-36) have been used in several clinical trials of treatment for GORD and have consistently shown that HR-QOL improves with successful therapy. These trials have been conducted primarily with two pharmacological agents, omeprazole and ranitidine. On the Heartburn-specific Quality of Life questionnaire, patients treated with ranitidine reported better HR-QOL after treatment compared with placebo therapy. In two clinical trials where omeprazole and ranitidine were compared, patients treated with omeprazole reported significantly better HR-QOL (based on the PGWB Index) than those treated with ranitidine; however, 2 other trials did not detect significant differences between the treatments. Results from clinical trials using disease-specific measures (Gastrointestinal Quality of Life Index [GIQLI] and Heartburn-specific Quality of Life questionnaire) demonstrate similar findings, supporting the association between treatment-related symptom resolution and improvements in HR-QOL. The GIQLI was used in a trial comparing pantoprazole and ranitidine, where results favoured pantoprazole therapy.

Several studies have demonstrated that resolution of GORD symptoms is associated with improvement in HR-QOL. Although there is evidence that treatment for GORD does improve symptoms and HR-QOL outcomes, further research is needed to more completely understand the value of medical therapy for GORD.

Keywords

Omeprazole Ranitidine Esomeprazole Pantoprazole Rabeprazole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. No conflicts of interest exist for the authors.

References

  1. 1.
    Goyal RK. Diseases of the esophagus. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., editors. Principles of internal medicine. New York (NY): McGraw Hill, 1994: 1355–62Google Scholar
  2. 2.
    Wiener GJ, Koufman JA, Wu WC, et al. Chronic hoarseness secondary to gastroesophageal reflux disease: documentation with 24-hour ambulatory pH monitoring. Am J Gastroenterol 1989; 84: 1503–8PubMedGoogle Scholar
  3. 3.
    Sontag SJ, O’Connell S, Khandelwal S, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990; 99: 613–90PubMedGoogle Scholar
  4. 4.
    Modlin IM, Sachs R. Acid-related diseases. Munich: Schnetztor-Verlag GmbH D-Konstantz, 1998Google Scholar
  5. 5.
    Nebel OT, Fornes MF, Castell DO. Symptomatic gastro-sophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953–6PubMedCrossRefGoogle Scholar
  6. 6.
    van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagon-ists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review). Available in the Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2001Google Scholar
  7. 7.
    Beers MH, Berkow R, editors. Gastrointestinal disorders: the Merck manual. 17th ed. Whitehouse Station (NJ): Merck Re-search Laboratories, 1999Google Scholar
  8. 8.
    Wolfe MM. An overview of gastroesophageal reflux disease. Am J Manag Care 2000; 6 Suppl.: S461–6Google Scholar
  9. 9.
    An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 Suppl. 2: S1–16Google Scholar
  10. 10.
    DeVault KR, Castell DO, on behalf of The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastro esophageal reflux disease. Am J Gastroenterol 1999; 94 (6): 1434–42PubMedCrossRefGoogle Scholar
  11. 11.
    Flynn CA. The evaluation and treatment of adults with gastroesophageal reflux disease. J Fam Pract 2001; 50: 57–63PubMedGoogle Scholar
  12. 12.
    SAGES (Society of American Gastrointestinal Endoscopic Sur-geons). Guidelines for surgical treatment of gastroesophageal reflux disease (GERD). Surg Endosc 1998; 12: 186–8CrossRefGoogle Scholar
  13. 13.
    Wiklund I. Quality of life in patients with gastroesophageal reflux disease. Am J Gastroenterol 2001; 96 (8 Suppl.): S46–53PubMedCrossRefGoogle Scholar
  14. 14.
    Rentz AM, Battista C, Trudeau E, et al. Symptom and health-related quality of life measures for selected gastrointestinal disease studies: a review and synthesis of the literature. Pharmacoeconomics 2001; 19 (4): 349–63PubMedCrossRefGoogle Scholar
  15. 15.
    DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994; 69: 867–76PubMedCrossRefGoogle Scholar
  16. 16.
    Ramirez B, Richter JE. Promotility drugs and the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 5–20PubMedCrossRefGoogle Scholar
  17. 17.
    Iskedjian M, Einarson TR. Meta-analyses of cisapride, omeprazole, and ranitidine in the treatment of GORD: implications for treating patient subgroups. Clin Drug Invest 1998; 16: 9–18CrossRefGoogle Scholar
  18. 18.
    Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Arch Intern Med 1996; 156: 477–82PubMedCrossRefGoogle Scholar
  19. 19.
    Humphries TJ, Merritt GJ. Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13: 18–26PubMedCrossRefGoogle Scholar
  20. 20.
    Bardhan KD. The role of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther 1995; 9: 15–25PubMedCrossRefGoogle Scholar
  21. 21.
    Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine-2 receptor antagonist therapy. Am J Gastroenterol 1997; 92: 429–37PubMedGoogle Scholar
  22. 22.
    Lansoprazole [package insert]. TAP Pharmaceuticals Inc., 2002Google Scholar
  23. 23.
    Omeprazole [package insert]. AstraZeneca, 2002Google Scholar
  24. 24.
    Moyer CA, Fendrick AM. Measuring health-related quality of life in patients with gastrointestinal disease. Dig Dis 1998; 16: 315–24PubMedCrossRefGoogle Scholar
  25. 25.
    Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 75–83PubMedCrossRefGoogle Scholar
  26. 26.
    Revicki DA, Wood M, Maton P, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252–8PubMedCrossRefGoogle Scholar
  27. 27.
    Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119–24PubMedCrossRefGoogle Scholar
  28. 28.
    Wiklund I, Glise H, Jerndal P, et al. Does endoscopy have a positive impact on quality of life in dyspepsia? Gastrointest Endosc 1998; 47: 449–54PubMedCrossRefGoogle Scholar
  29. 29.
    Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94 (7): 1783–90CrossRefGoogle Scholar
  30. 30.
    Kaplan-Machlis B, Spiegler G, Zodet MW, et al. Effectiveness and costs of omeprazole vs ranitidine for treatment of Symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000; 9: 624–30PubMedCrossRefGoogle Scholar
  31. 31.
    Lundell L, Miettinen P, Myrvold HE, et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 2000; 12 (8): 879–87PubMedCrossRefGoogle Scholar
  32. 32.
    Revicki DA, Ehreth JL. Health-related quality of life assessment and planning for the pharmaceutical industry. Clin Ther 1997; 19: 1101–15PubMedCrossRefGoogle Scholar
  33. 33.
    Kaplan-Machlis B, Spiegler G, Revicki DA. Health-related quality of life in primary care patients with gastroesophageal reflux disease. Ann Pharmacother 1999; 33: 1032–6PubMedCrossRefGoogle Scholar
  34. 34.
    Young TL, Krichdoerfer LJ, Osterhaus JT. A development and validation process for a disease-specific quality of life instrument. Drug Inform J 1996; 30: 185–93CrossRefGoogle Scholar
  35. 35.
    Revicki DA, Sorensen S, Maton P, et al. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998; 16: 284–91PubMedCrossRefGoogle Scholar
  36. 36.
    Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 1621–30PubMedCrossRefGoogle Scholar
  37. 37.
    Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 1993; 28: 18–21CrossRefGoogle Scholar
  38. 38.
    Ware J. SF-36 Health survey manual and interpretation guide. Boston (MA): The Health Institute, New England Medical Center, 1993Google Scholar
  39. 39.
    Dupuy HJ. The psychological general well-being (PGWB) index. In: Wender NK, Mattson ME, Furberg CD, et al., editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York (NY): Le Jacq, 1984: 170–83Google Scholar
  40. 40.
    Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal quality of life index: development, validation, and application of a new instrument. Br J Surg 1995; 82: 216–22PubMedCrossRefGoogle Scholar
  41. 41.
    Wiklund I, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients: psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 164: 41–9CrossRefGoogle Scholar
  42. 42.
    Raymond JM, Marquis P, Bechade D, et al. Assessment of quality of life of patients with gastroesophageal reflux: elaboration and validation of a specific questionnaire [in French]. Gastroenterol Clin Biol 1999; 23 (1): 32–9PubMedGoogle Scholar
  43. 43.
    Marquis P, Sapede C, Bechade D, et al. Development and psychometric validation of a disease-specific quality of life questionnaire in gastro-oesophageal reflux. Qual Life Res 1995; 4: 457–8CrossRefGoogle Scholar
  44. 44.
    Colwell HH, Mathias SD, Pasta DJ, et al. Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study. Dig Dis Sci 1999 Jul; 44 (7): 1376–83PubMedCrossRefGoogle Scholar
  45. 45.
    Rush DR, Stelmach WJ, Young TL, et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastro-esophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995; 41 (2): 126–36PubMedGoogle Scholar
  46. 46.
    Chat KL, Stacey JH, Sacks GE. The effect of ranitidine on symptom relief and quality of life of patients with gastrooesophageal reflux disease. Br J Clin Pract 1995; 49 (2): 73–7Google Scholar
  47. 47.
    Kaspari S, Biedermann A, Mey J. Comparison of pantoprazole 20mg to ranitidine 150mg BID in the treatment of mild gastro-esophageal reflux disease. Digestion 2001; 63: 163–70PubMedCrossRefGoogle Scholar
  48. 48.
    Stacey JH, Miocevich ML, Sacks GE. The effect of ranitidine (as effervescent tablets) on the quality of life of GORD patients. Br J Clin Pract 1996; 50 (4): 190–4, 196PubMedGoogle Scholar
  49. 49.
    Watson RGP, Tham TCK, Johnston BT, et al. Double-blind cross-over placebo-controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux: the “sensitive oesophagus”. Gut 1997; 40: 587–90PubMedGoogle Scholar
  50. 50.
    Oster G, Thompson D, Kaatz S, et al. The GORD outcomes trial: a randomized study to assess outcomes and costs in primary care practice [abstract]. Gastroenterology 1998; 114: A32CrossRefGoogle Scholar
  51. 51.
    Wiklund I, Bardhan KD, Müller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine: re sults from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998; 30: 19–27PubMedGoogle Scholar
  52. 52.
    Lauritsen K, Junghard O, Eklund S, et al. Effect of esomeprazole 40 mg on healing, reflux symptoms, and quality of life in patients with reflux esophagitis [abstract]. Presented at the Annual Meeting for Digestive Disease Week, American Gastroenterological Association; 2002 May 19–22; San Francisco (CA)Google Scholar
  53. 53.
    Schipper H, Clinch JJ, Olweny CLM. Quality of life studies: definition and conceptual issues. In: Spiler B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Press, 1996Google Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Manishi Prasad
    • 1
  • Anne M. Rentz
    • 1
  • Dennis A. Revicki
    • 1
  1. 1.MEDTAP InternationalBethesdaUSA

Personalised recommendations